Merit Medical Systems (NASDAQ:MMSI) Posts Earnings Results

Merit Medical Systems (NASDAQ:MMSI) announced its earnings results on Thursday. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23, FiscalAI reports. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The firm had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. During the same quarter in the prior year, the business posted $1.01 EPS. The business’s revenue was up 9.5% compared to the same quarter last year. Merit Medical Systems updated its FY 2026 guidance to 4.250-4.350 EPS.

Here are the key takeaways from Merit Medical Systems’ conference call:

• Merit reported 9% organic constant-currency revenue growth in Q2, its strongest quarterly organic growth in three years, with broad-based strength across foundational and therapeutic products, including vascular intervention, access, cardiac therapies, endoscopy, and OEM.
• Q2 profitability exceeded expectations: non-GAAP operating margin rose to 22.6%, non-GAAP EPS increased 18% to $1.19, and free cash flow reached nearly $52 million. Excluding a $0.09-per-share tariff refund benefit, EPS was still $1.10 and above guidance.
• The company raised its 2026 outlook, now expecting 6.9%-7.6% constant-currency revenue growth and non-GAAP EPS of $4.25-$4.35, versus prior EPS guidance of $4.01-$4.15; organic growth guidance increased to 6.9%-7.5%.
• Acquisitions are performing ahead of expectations: BioLife’s annualized 2026 revenue outlook increased to approximately $23 million, while C2 CryoBalloon remains expected to generate $8 million-$9 million. Merit also launched SCOUT MD and is introducing View Point Medical’s OneMark system to expand its oncology localization offering.
• Management expects third-quarter revenue and EPS to moderate sequentially because of normal summer seasonality, while ongoing tariffs are expected to reduce 2026 results by approximately $16 million, or $0.21 per share; tariff policy uncertainty also contributed to a wider Q3 margin and EPS outlook range.

Merit Medical Systems Price Performance

Shares of Merit Medical Systems stock traded up $2.51 on Thursday, reaching $83.35. 2,024,596 shares of the stock were exchanged, compared to its average volume of 691,109. The firm’s 50 day moving average is $69.45 and its 200-day moving average is $71.69. Merit Medical Systems has a one year low of $59.74 and a one year high of $94.75. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.46 and a current ratio of 5.08. The firm has a market cap of $4.97 billion, a PE ratio of 36.08, a P/E/G ratio of 2.51 and a beta of 0.52.

Insider Buying and Selling

In other news, insider Brian G. Lloyd acquired 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were acquired at an average cost of $62.62 per share, with a total value of $125,240.00. Following the completion of the purchase, the insider directly owned 2,000 shares of the company’s stock, valued at $125,240. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Lynne N. Ward sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the transaction, the director owned 7,809 shares of the company’s stock, valued at approximately $488,921.49. This represents a 39.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

A number of institutional investors have recently modified their holdings of MMSI. Los Angeles Capital Management LLC bought a new stake in shares of Merit Medical Systems during the 4th quarter worth $25,000. Danske Bank A S acquired a new stake in Merit Medical Systems in the third quarter valued at about $42,000. Quarry LP grew its position in Merit Medical Systems by 185.9% in the third quarter. Quarry LP now owns 526 shares of the medical instruments supplier’s stock valued at $44,000 after acquiring an additional 342 shares during the last quarter. Global Retirement Partners LLC grew its position in Merit Medical Systems by 973.6% in the fourth quarter. Global Retirement Partners LLC now owns 569 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 516 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in Merit Medical Systems by 745.9% during the second quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock worth $86,000 after acquiring an additional 813 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.

Analyst Ratings Changes

MMSI has been the subject of several recent research reports. Compass Point set a $107.00 price target on Merit Medical Systems in a research note on Monday, April 20th. Citigroup restated an “outperform” rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Barrington Research dropped their price objective on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a report on Monday, April 20th. Wall Street Zen downgraded Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 5th. Finally, Weiss Ratings lowered Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $92.80.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.